Wang L, Zhang M, Zhao K, Yuan X, Zhao H, Liu Y
Front Oncol. 2025; 15:1451130.
PMID: 40046628
PMC: 11881191.
DOI: 10.3389/fonc.2025.1451130.
Caceres A, Perez-Jurado L, Alegret-Garcia A, Dwaraka V, Smith R, Gonzalez J
Commun Biol. 2025; 8(1):289.
PMID: 39987288
PMC: 11846847.
DOI: 10.1038/s42003-025-07691-y.
Lee S, Ricci B, Tran J, Eul E, Ye J, Ren Q
Nat Commun. 2025; 16(1):1183.
PMID: 39885132
PMC: 11782527.
DOI: 10.1038/s41467-025-56420-w.
Sikder S, Bhattacharya A, Agrawal A, Sethi G, Kundu T
Heliyon. 2024; 10(19):e38193.
PMID: 39386816
PMC: 11462366.
DOI: 10.1016/j.heliyon.2024.e38193.
Zhang W, Xiao Y, Zhu X, Zhang Y, Xiang Q, Wu S
J Inflamm Res. 2024; 17:4721-4746.
PMID: 39051055
PMC: 11268618.
DOI: 10.2147/JIR.S458832.
Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.
Carey-Smith S, Kotecha R, Cheung L, Malinge S
Int J Mol Sci. 2024; 25(13).
PMID: 38999925
PMC: 11241182.
DOI: 10.3390/ijms25136815.
Systematic proteomics analysis revealed different expression of laminin interaction proteins in breast cancer: lower in luminal subtype and higher in claudin-low subtype.
Gao X, Pan T, Duan W, Zhu W, Liu L, Liu Y
Transl Cancer Res. 2024; 13(5):2108-2121.
PMID: 38881926
PMC: 11170511.
DOI: 10.21037/tcr-23-2214.
Oncogenes and tumor suppressor genes: functions and roles in cancers.
Dakal T, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V
MedComm (2020). 2024; 5(6):e582.
PMID: 38827026
PMC: 11141506.
DOI: 10.1002/mco2.582.
Identification of exosome-related gene signature as a promising diagnostic and therapeutic tool for breast cancer.
Chen Q, Zhou Q
Heliyon. 2024; 10(8):e29551.
PMID: 38665551
PMC: 11043961.
DOI: 10.1016/j.heliyon.2024.e29551.
Transcriptome signatures of host tissue infected with African swine fever virus reveal differential expression of associated oncogenes.
Deb R, Sengar G, Sonowal J, Pegu S, Das P, Singh I
Arch Virol. 2024; 169(3):54.
PMID: 38381218
DOI: 10.1007/s00705-023-05959-4.
Pan-caner analysis identifies PSMA7 as a targets for amplification at 20q13.33 in tumorigenesis.
Sheng G, Li F, Jin W, Wang K
Sci Rep. 2024; 14(1):3034.
PMID: 38321088
PMC: 10847487.
DOI: 10.1038/s41598-024-53585-0.
Long noncoding RNA DLEU2 and ROR1 pathway induces epithelial-to-mesenchymal transition and cancer stem cells in breast cancer.
Islam S, Al-Tweigeri T, Al-Harbi L, Ujjahan S, Al-Mozaini M, Tulbah A
Cell Death Discov. 2024; 10(1):61.
PMID: 38296962
PMC: 10830457.
DOI: 10.1038/s41420-024-01829-3.
NOP16 promotes hepatocellular carcinoma progression and triggers EMT through the Keap1-Nrf2 signaling pathway.
Mu S, Tian Q, Shen L
Technol Health Care. 2024; 32(4):2463-2483.
PMID: 38251077
PMC: 11322705.
DOI: 10.3233/THC-231256.
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams N, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S
Ther Adv Med Oncol. 2023; 15:17588359231217976.
PMID: 38152697
PMC: 10752118.
DOI: 10.1177/17588359231217976.
The expression of O-linked glycosyltransferase GALNT7 in breast cancer is dependent on estrogen-, progesterone-, and HER2-receptor status, with prognostic implications.
Berkel C, Cacan E
Glycoconj J. 2023; 40(6):631-644.
PMID: 37947928
DOI: 10.1007/s10719-023-10137-4.
Establishing the Link between X-Chromosome Aberrations and Status, with Breast Cancer Patient Outcomes.
Caramia F, Speed T, Shen H, Haupt Y, Haupt S
Cells. 2023; 12(18).
PMID: 37759468
PMC: 10526523.
DOI: 10.3390/cells12182245.
Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.
Zhang J, Wei Z, Qi X, Jiang Y, Liu D, Liu K
Funct Integr Genomics. 2023; 23(3):284.
PMID: 37648881
DOI: 10.1007/s10142-023-01209-7.
A cell cycle centric view of tumour dormancy.
Weston W, Barr A
Br J Cancer. 2023; 129(10):1535-1545.
PMID: 37608096
PMC: 10645753.
DOI: 10.1038/s41416-023-02401-z.
Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A.
Cacioppo R, Akman H, Tuncer T, Erson-Bensan A, Lindon C
Elife. 2023; 12.
PMID: 37384380
PMC: 10328522.
DOI: 10.7554/eLife.87253.
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.
Dahlgren M, Lettiero B, Dalal H, Martensson K, Gaber A, Nodin B
BMC Res Notes. 2023; 16(1):105.
PMID: 37322548
PMC: 10268435.
DOI: 10.1186/s13104-023-06376-1.